MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 140 filers reported holding MERSANA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $163,915 | -66.4% | 129,067 | -13.1% | 0.00% | – |
| Q2 2023 | $488,443 | +14.4% | 148,463 | +42.9% | 0.00% | – |
| Q1 2023 | $426,943 | -25.3% | 103,879 | +6.6% | 0.00% | -100.0% |
| Q4 2022 | $571,197 | -17.6% | 97,474 | -5.1% | 0.00% | 0.0% |
| Q3 2022 | $693,000 | +85.8% | 102,667 | +27.5% | 0.00% | – |
| Q2 2022 | $373,000 | +22.7% | 80,542 | +6.0% | 0.00% | – |
| Q1 2022 | $304,000 | -26.7% | 75,957 | +13.8% | 0.00% | – |
| Q4 2021 | $415,000 | -15.7% | 66,721 | +28.1% | 0.00% | – |
| Q3 2021 | $492,000 | -33.2% | 52,096 | -3.8% | 0.00% | – |
| Q2 2021 | $736,000 | -14.7% | 54,157 | +1.3% | 0.00% | – |
| Q1 2021 | $863,000 | -71.4% | 53,442 | -52.8% | 0.00% | -100.0% |
| Q4 2020 | $3,013,000 | +43.5% | 113,240 | +0.4% | 0.00% | 0.0% |
| Q3 2020 | $2,100,000 | +55.3% | 112,743 | +95.2% | 0.00% | 0.0% |
| Q2 2020 | $1,352,000 | +7852.9% | 57,772 | +431.6% | 0.00% | – |
| Q3 2019 | $17,000 | – | 10,868 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 796,458 | $14,830,000 | 12.35% |
| Consonance Capital Management LP | 3,468,171 | $64,577,000 | 7.87% |
| Sarissa Capital Management LP | 2,837,000 | $52,824,000 | 6.22% |
| Bain Capital Life Sciences Investors, LLC | 3,445,667 | $64,158,000 | 5.98% |
| Ghost Tree Capital, LLC | 1,050,000 | $19,551,000 | 5.65% |
| NEA Management Company, LLC | 5,959,520 | $110,966,000 | 4.70% |
| Soleus Capital Management, L.P. | 393,041 | $7,318,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 667,500 | $12,429,000 | 3.38% |
| Avoro Capital Advisors LLC | 6,800,000 | $126,616,000 | 1.80% |
| FNY Investment Advisers, LLC | 199,800 | $3,720,000 | 1.57% |